C82.57
Diffuse follicle center lymphoma, spleen
Clinical Classification Guidelines
Medical Intelligence & Overview
Diffuse follicle center lymphoma of the spleen is a type of non-Hodgkin lymphoma, a cancer that originates in the lymphatic system, specifically affecting lymphocytes in the follicle centers of lymph nodes and other lymphatic tissues such as the spleen. This condition involves malignant growth of B-cells and can cause lymphoma to develop within the spleen, leading to its enlargement and affecting immune function. Precise diagnosis and management are crucial for optimizing patient outcomes.
Causes & Symptoms
Clinical Causes: Genetic mutations leading to abnormal B-cell growth Immune system dysregulation Environmental exposures, such as pesticides or chemicals (though specific causes are often unknown) Infections that may trigger abnormal immune responses
Key Symptoms: Splenomegaly (enlargement of the spleen), which may cause discomfort or pain in the upper left abdomen Unexplained weight loss Fatigue or weakness Fever and night sweats Lymphadenopathy (swollen lymph nodes) Frequent infections due to immune suppression Early satiety or feeling full quickly
Diagnostic & Treatment
Diagnosis Path: Diagnosis of diffuse follicle center lymphoma of the spleen involves several steps: - Physical examination to detect spleen enlargement and lymph node swelling - Imaging studies such as ultrasound, CT scans, or PET scans to evaluate organ involvement - Blood tests to assess blood cell counts and overall health - Biopsy of affected tissue (spleen or lymph nodes) to examine under a microscope for malignant lymphocytes - Immunophenotyping and genetic testing to identify specific markers associated with the lymphoma - Bone marrow biopsy might be performed to determine the extent of disease spread
Treatment Protocols: Treatment approaches typically depend on the stage and overall health of the patient and may include: - Chemotherapy to destroy cancerous cells - Immunotherapy, such as monoclonal antibodies, to target lymphoma cells - Targeted therapy aimed at specific genetic mutations - Radiation therapy in select cases - Stem cell transplantation in cases resistant to initial treatments It is critical to consult with a hematologist or oncologist to determine the most suitable treatment plan, as individual cases vary widely.
Clinical Advice & FAQs
Billing Guidance
Is C82.57 a billable ICD-10 code?
Yes, C82.57 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C82.57?
Clinical documentation must specify the nature of Diffuse follicle center lymphoma, spleen and any associated comorbidities for accurate reporting.
Cite this Clinical Reference